Walter Blättler

Chairman at

35Pharma, Inc.

77 year

68 connections

Health Technology

Consumer Services

Commercial Services

Profile

Walter A. Blättler was the founder of Semma Therapeutics, Inc. founded in 2015, where he held the title of Vice President-Manufacturing.
He currently holds the position of Chairman at Formation Biologics Corp.
and 35Pharma, Inc. Dr. Blättler's former positions include Director-Pre Clinical Development at Proterris (Portugal) -.
Investigação e Desenvolvimento from 2009 to 2011, Director at Bristol-Myers Squibb FCT bêta, Inc. from 2014 to 2020, Executive Vice President-Science & Technology at ImmunoGen, Inc. from 1987 to 2007, Independent Member-Supervisory Board at MorphoSys AG from 2007 to 2015, and Vice President-Development at CoStim Pharmaceuticals, Inc. from 2012 to 2014.
Dr. Blättler's education includes a graduate degree from Swiss Federal Institute of Technology in 1973 and a doctorate degree from Swiss Federal Institute of Technology in 1978.

Walter Blättler active positions

Companies	Position	Start
35Pharma, Inc. 35Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in designing and developing of TGF-beta superfamily therapeutics	Chairman	-

All active positions of Walter Blättler

Former positions of Walter Blättler

Companies	Position	End
Bristol-Myers Squibb FCT bêta, Inc. Bristol-Myers Squibb FCT bêta, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-tumor activity medication treatment	Director/Board Member	2020-09-20
MORPHOSYS AG	Director/Board Member	2015-05-07
CoStim Pharmaceuticals, Inc. CoStim Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotech company which develops biologics for oncology indications	Corporate Officer/Principal	2013-12-31
Proterris (Portugal) - Investigação e Desenvolvimento Proterris (Portugal) - Investigação e Desenvolvimento Pharmaceuticals: GenericHealth Technology Develops small-molecule drugs for the treatment of inflammation-related diseases	Corporate Officer/Principal	2010-12-31
IMMUNOGEN, INC.	Corporate Officer/Principal	2007-03-04

See the detail of Walter Blättler's experience

Training of Walter Blättler

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Walter Blättler's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	9
ImmunoGen, Inc. ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics	Health Technology
MorphoSys AG MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services	Health Technology
Swiss Federal Institute of Technology Swiss Federal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Proterris (Portugal) - Investigação e Desenvolvimento Proterris (Portugal) - Investigação e Desenvolvimento Pharmaceuticals: GenericHealth Technology Develops small-molecule drugs for the treatment of inflammation-related diseases	Health Technology
Bristol-Myers Squibb FCT bêta, Inc. Bristol-Myers Squibb FCT bêta, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-tumor activity medication treatment	Health Technology
CoStim Pharmaceuticals, Inc. CoStim Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotech company which develops biologics for oncology indications	Health Technology
Semma Therapeutics, Inc. Semma Therapeutics, Inc. BiotechnologyHealth Technology Develops transformative therapies for patients who currently depend on insulin injections	Health Technology
Formation Biologics Corp. Formation Biologics Corp. Miscellaneous Commercial ServicesCommercial Services Operates clinical stage company that designs and develops bio therapeutics for treatment of cancer & fibrotic diseases	Commercial Services
35Pharma, Inc. 35Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in designing and developing of TGF-beta superfamily therapeutics	Health Technology